|
|
Study on the Efficacy of Thoracoscopic Surgery for Mediastinal Tumors by Lateral Thoracic Approach and Subxiphoid Approach |
SUN Jian, GAO Congrong, PEI Shaohua |
Hefei Second People's Hospital, Anhui Hefei 230000, China |
|
|
Abstract Objective: To study the efficacy of thoracoscopic surgery via lateral thoracic approach and subxiphoid approach in the treatment of mediastinal tumor (MT) and its influence on the levels of plasma pain-causing factors. Methods: Totally 118 patients with MT in the hospital from June 2020 to June 2023 were selected, and were divided into lateral thoracic group (thoracoscopic surgery via lateral thoracic approach, n=46) and xiphoid group (thoracoscopic surgery via subxiphoid approach, n=72) according to the surgical approaches. The propensity score method was used for 1∶1 matching, and 43 cases were included in each group. The surgical indicators, postoperative pain, pain-causing factors, incidence rates of postoperative complications, recurrence rate and survival status at 1 year after surgery were compared between groups. Results: The extubation time and analgesic days in xiphoid process group were shorter than those in lateral chest group, the differences were statistically significant (P<0.05). The scores of numerical rating scale (NRS) at T1, T2 and T3 in the xiphoid group with (3.53±0.86) points, (2.46±0.65) points and (1.67±0.41) points were lower than (4.26±1.18) points, (3.73±0.92) points and (2.18±0.54) points in the lateral thoracic group (P<0.05). Serum bradykinin (BK), neuropeptide Y (NPY) and prostaglandin E2 (PGE2) in the xiphoid group at T1, T2 and T3 were lower compared with those in the lateral thoracic group (P<0.05). There was no significant difference in total complications between xiphoid process group (6.99%) and lateral chest group (13.98%) (P>0.05). There was no significant difference in postoperative recurrence rate (2.33% vs 2.33%) and fatality rate (0% vs 2.33%) between the two groups (P>0.05). Conclusion: Thoracoscopic surgery via subxiphoid approach for patients with MT can effectively shorten the postoperative extubation time and analgesic use time, and reduce the levels of postoperative pain-causing factors, and it has high treatment safety.
|
|
|
|
|
[1] Ito R,Tsukioka T,Izumi N,et al.Artificial pneumothorax suppresses postoperative inflammatory reaction in mediastinal tumor surgery[J].Gen Thorac Cardiovasc Surg,2022,70(3):257-264. [2] 陈秀科,李东涛,张福维,等.剑突入路胸腔镜手术对前纵隔肿瘤患者应激指标及血清肿瘤标志物影响[J].临床军医杂志,2023,51(4):397-400. [3] Chen H,Xu B,Zhang Q,et al.Anterior mediastinal tumor surgery applying single-port thoracoscopy using the subxiphoid approach[J].Turk Gogus Kalp Damar Cerrahisi Derg,2023,31(2):239-248. [4] 中国医师协会医学机器人医师分会胸外科专业委员会筹备组.机器人辅助纵隔肿瘤手术中国专家共识(2019版)[J].中国胸心血管外科临床杂志,2020,27(2):117-125. [5] He S,Renne A,Argandykov D,et al.Comparison of an emoji-based visual analog scale with a numeric rating scale for pain assessment[J].JAMA,2022,328(2):208-209. [6] Mao T,Zhang X,Yang Y,et al.A uniport subxiphoid approach with a modified sternum retractor is safe and feasible for anterior mediastinal tumors[J].Thorac Dis,2023,15(3):1364-1372. [7] 洪子强,盛燕楠,白向豆,等.达芬奇机器人辅助经剑突下与经侧胸入路治疗前纵隔肿瘤的临床疗效比较[J].肿瘤防治研究,2023,50(6):598-602. [8] 陈世雄,许家君,陈胜家,等.剑突下入路胸腔镜前纵隔肿瘤切除术24例[J].中国微创外科杂志,2023,23(5):332-335. [9] 孙振栋,周一凡,徐睿宏,等.经剑突入路达芬奇机器人手术与电视胸腔镜手术治疗前纵隔肿瘤疗效比较[J].中国临床新医学,2024,17(4):448-452. [10] Sezen CB,Dogru MV,Tanrikulu G,et al.Comparison of short-term results of subxiphoid and conventional video-assisted thoracoscopic surgery in diagnostic wedge resections[J].Asian Cardiovasc Thorac Ann,2023,31(2):115-122. [11] Lv L,Yu B,Zhai Y,et al.Surgical removal of bilateral lung metastases from Wilms tumor via subxiphoid approach video-assisted thoracic surgery:a case report[J].Transl Pediatr,2022,11(8):1408-1414. [12] Linhares SSG,Meurer YDSR,Aquino A,et al.Effects of prenatal exposure to fluoxetine on circadian rhythmicity in the locomotor activity and neuropeptide Y and 5-HT expression in male and female adult Wistar rats[J].Int Dev Neurosci,2022,82(5):407-422. [13] Chivers SB,Brackley AD,Jeske NA.Raf kinase inhibitory protein reduces bradykinin receptor desensitization[J].Neurochem,2022,162(2):156-165. |
|
|
|